ClinicalTrials.gg
Active, not recruitingNCT06223516Updated Mar 27, 2026

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1 interventional study of Subcutaneous (SC) Etentamig and Intravenous (IV) Etentamig in Multiple Myeloma, sponsored by AbbVie. Active, not recruiting at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing etentamig in Multiple Myeloma — 6 open to participants now, 10 under way, 3 of them phase 3. etentamig · Multiple Myeloma.

Enrollment
9th of 10
60 · median 235
Started
2024
with 1 other
Phase 1
4 of 10
2 open now
Registered
5th of 10
by date
Lead sponsor
9 of 10
AbbVie

Among the 10 studies testing etentamig in Multiple Myeloma, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 4 in phase 1, and was the 5th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 10 studies testing etentamig in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About etentamig

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing etentamig in Multiple Myeloma, or all of them as a file.
02

Study summary

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of Etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM.

Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R MM. This study is broken into 3 Arms: Arm A with 2 parts and Arm B as an expansion. Participants will receive ABBV-383 as a subcutaneous (SC) injection and intravenous (IV) infusion in Arm A and SC injections of ABBV-383 in Arm B. Around 55 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 15 sites across the world

In Arm A participants will receive one of two doses of Etentamig (ABBV-383) as an SC injection and (IV) infusions, during the 151 week study duration. In Arm B, participants will receive the selected dose from Arm A as SC injections, during the 151 week study duration.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • ABBV-383
  • Etentamig
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance of \<= 2.
  • Participants with multiple myeloma who have received 3-5 and with prior triple class exposure including a proteasome inhibitor, anti-CD38 monoclonal antibody and an immunomodulatory drug.
  • Must be naïve to treatment with ABBV-383.

Exclusion criteria

Exclusion Criteria:

- Received B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Etentamig Dose A

    Participants will receive Dose A of Etentamig as a subcutaneous (SC) injection and intravenous (IV) infusions, during the 151 week study duration.

    Drug: Subcutaneous (SC) Etentamig · Drug: Intravenous (IV) Etentamig

  • Experimental
    Etentamig Dose B

    Participants will receive Dose B of Etentamig as an SC injection and IV infusions, during the 151 week study duration.

    Drug: Subcutaneous (SC) Etentamig · Drug: Intravenous (IV) Etentamig

  • Experimental
    Etentamig Expansion

    Participants will receive the selected dose from Arm A of Etentamig as SC injections, during the 151 week study duration.

    Drug: Subcutaneous (SC) Etentamig

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Cytokine Release Syndrome (CRS) Events

    Cytokine Release Syndrome events will be graded using American Society for Transplantation and Cellular Therapy (ASTCT), with a higher grade indicating higher severity.

    Time frame: Up to 2 cycles (56 days)

  2. Percentage of Participants Experiencing Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events

    ICANS events will be graded using ASTCT, with a higher grade indicating higher severity.

    Time frame: Up to 2 cycles (56 days)

  3. Maximum Observed Concentration (Cmax) of ABBV-383

    Cmax of ABBV-383.

    Time frame: Up to 32 weeks

  4. Time to Cmax (Tmax) of ABBV-383

    Tmax of ABBV-383.

    Time frame: Up to 32 weeks

  5. Trough Concentration (Ctrough) of ABBV-383

    Ctrough of ABBV-383.

    Time frame: Up to 32 weeks

  6. Area Under the Plasma Concentration-time Curve (AUC) of ABBV-383

    AUC of ABBV-383.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Overall Response Rate (ORR)

    The ORR is defined as the percentage of participants who achieve a best overall response of confirmed PR or better determined by international myeloma working group (IMWG) criteria, prior to the initiation of subsequent myeloma therapy.

    Time frame: Up to 24 months

  2. Percentage of Participants Achieving Stringent Complete Response (sCR),

    sCR is defined as participants achieving negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, \< 5% plasma cells in bone marrow, normal free light chain (FLC) ratio, and Absence of clonal cells in bone marrow by immunohistochemistry.

    Time frame: Up to 24 months

  3. Percentage of Participants Achieving Complete Response (CR)

    CR is defined as participants achieving negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, \< 5% plasma cells in bone marrow, and for participants in whom the only measurable disease is by serum FLC levels, a normal FLC ratio.

    Time frame: Up to 24 months

  4. Percentage of Participants Achieving Very Good Partial Response (VGPR)

    VGPR is defined as participants achieving serum and urine M-protein detectable by immunofixation but not on electrophoresis, \>= 90% reduction in serum M-protein plus urine, and for participants in whom the only measurable disease is by serum FLC levels, \>= 90% decrease in the difference between involved and uninvolved FLC levels.

    Time frame: Up to 24 months

  5. Percentage of Participants Achieving Partial Response (PR)

    PR is defined as participants achieving \>= 50% reduction of serum M-protein, reduction in 24-hour urinary M-protein by \>= 90% as noted in the protocol, \>= 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline.

    Time frame: Up to 24 months

  6. Duration of Response (DoR)

    DoR will be defined as the time from the date of first response \[partial response (PR) + VGPR + complete response (CR) + stringent complete response (sCR)\] to the earliest occurrence of progressive disease, or death, whatever occurs first.

    Time frame: Up to 24 months

  7. Progression Free Survival (PFS)

    PFS is defined as the duration from the date of randomization to the date of confirmed disease progression (PD) per international myeloma working group (IMWG) criteria, or death, whichever occurs first.

    Time frame: Up to 24 months

  8. Time to Response (TTR)

    TTR is defined as the number of months from the date of first dose to the date of best overall response of CR or PR ('responders') determined by IMWG criteria.

    Time frame: Up to 24 months

  9. Immunogenicity of ABBV-383 as Determined by Anti-Drug Antibodies (ADAs)

    Incidence and concentration of ADAs.

    Time frame: Up to 27 months

  10. Immunogenicity of ABBV-383 as Determined by Neutralizing Anti-Drug Antibodies (NAbs)

    Incidence and concentration of NAbs.

    Time frame: Up to 27 months

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Feb 2027, 32 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 32 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2024
First posted
Jan 25, 2024
StartActual
Jun 17, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Dec 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06223516
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Jun 17, 2024
Primary completion
Feb 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etentamig

Start the discussion